The content discusses the complex decision-making process that oncologists face when considering genomic testing for their cancer patients. Key points:
Genomic testing has become the standard of care in oncology, but oncologists are still grappling with factors that influence their decision to order such tests.
A 2017 survey found that nearly half of oncologists (47%) said that knowledge of the patient's insurance coverage is a very significant factor in their decision to order genomic testing, as they are concerned that insurance may not cover the costs.
Additionally, over 60% of oncologists are very concerned about the out-of-pocket costs for patients, even if insurance partially covers the testing, as the tests can be quite expensive (over $1000).
This financial consideration is an important factor, as genomic testing can provide crucial information to guide cancer treatment, and missing out on such testing could mean missing out on potentially lifesaving therapies.
The author emphasizes the need for more societal discussion and solutions to address the healthcare payment system issues that are influencing oncologists' decisions around genomic testing for their patients.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Maurie at www.medscape.com 06-13-2024
https://www.medscape.com/viewarticle/genomic-testing-oncologists-financial-concerns-2024a1000a15Deeper Inquiries